KBPH — Kyto Technology and Life Science Balance Sheet
0.000.00%
FinancialsHighly SpeculativeMicro Cap
Annual balance sheet for Kyto Technology and Life Science, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2017 March 31st | 2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0 | 0 | 0.094 | 0.034 | 1.44 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 0.001 | 0.001 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0 | 0.007 | 0.095 | 0.034 | 1.61 |
Long Term Investments | |||||
Total Assets | 0 | 0.007 | 1.59 | 2.7 | 8.43 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.226 | 0.324 | 0.029 | 0.032 | 1.44 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.226 | 0.324 | 0.029 | 0.032 | 1.44 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -0.226 | -0.317 | 1.56 | 2.67 | 6.99 |
Total Liabilities & Shareholders' Equity | 0 | 0.007 | 1.59 | 2.7 | 8.43 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |